The University of Cincinnati Cancer Center’s Maria F. Czyzyk-Krzeska was awarded a five-year, $2.8 million grant from the NIH to investigate how copper contributes to the advancement and recurrence of the most common type of kidney cancer, clear cell renal cell carcinoma.
UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.
